VF Corp vs GeneDx Holdings Corp — how do they compare? VF Corp trades at $14.89 (market cap $5.81B), while GeneDx Holdings Corp trades at $83.6 (market cap $2.44B). The key difference: VF Corp is far larger — about 2.4× GeneDx Holdings Corp's market cap, and VF Corp pays a 2.44% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| VFC | WGS | |
|---|---|---|
Market Cap | $5.81B | $2.44B |
Sector | Consumer Cyclical | Technology |
52-Week High | $21.55 | $167.51 |
52-Week Low | $12.21 | $34.51 |
Enterprise Value | $10.09B | $2.48B |
Dividend Yield | 2.44% | — |
Signals from Pluang's Aura AI — not financial advice
VFC trades at $14.90, down 0.6% on the day, near the low end of analyst targets. Technical indicators are bearish, with mixed recent earnings showing a Q4 beat but Q1 and Q2 misses. Revenue has declined from $11.8B in 2022 to $9.5B in 2025, with net losses in 2024 and 2025, though 2026 projects a return to profitability. The company faces brand-specific headwinds, particularly with Vans, while maintaining a reasonable P/S ratio of 0.62.
The outlook is cautious. Deleveraging progress and a raised 2027 revenue outlook offer some optimism, but persistent Vans weakness and macro pressures pose significant risks. Analyst consensus is Hold, with a $17.44 price target suggesting limited upside from current levels amid ongoing operational challenges.
No Aura AI signal available yet.
Trailing returns across standard periods
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →